Page 4 - Neil Kumar News Today

– Project ‘NADER’ is intended to span multiplephases, starting from mapping rare diseases in the UAE and wider region through innovative risk assessment algorithms, and moving towards clinical trials with

UAE-based Burjeel Holdings and US-based BridgeBio Pharma have announced a new project to revolutionise the field of early diagnosis and treatment of rare diseases or disorders in the UAE and the region.

Burjeel Holdings, one of the largest healthcare providers in

BridgeBio Pharma, Inc. (NASDAQ:BBIO – Free Report) shares shot up 5.9% on Wednesday . The stock traded as high as $17.40 and last traded at $17.25. 999,382 shares were traded during trading, a decline of 60% from the average session volume of 2,467,842 shares. The stock had previously closed at $16.29. Analysts Set New Price […]

BridgeBio Pharma, Inc. (NASDAQ:BBIO – Free Report)’s share price dropped 3.9% during mid-day trading on Thursday . The stock traded as low as $17.19 and last traded at $17.31. Approximately 1,190,509 shares changed hands during mid-day trading, a decline of 52% from the average daily volume of 2,470,749 shares. The stock had previously closed at […]

BridgeBio Pharma, Inc. (NASDAQ:BBIO – Get Rating)’s share price traded up 6.3% during mid-day trading on Tuesday . The stock traded as high as $15.99 and last traded at $15.96. 893,814 shares changed hands during trading, a decline of 64% from the average session volume of 2,491,820 shares. The stock had previously closed at $15.01. […]

Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO – Get Rating) have received a consensus recommendation of “Buy” from the nine ratings firms that are currently covering the firm, Marketbeat reports. Nine analysts have rated the stock with a buy rating. The average 12 month price target among brokerages that have updated their coverage on the stock […]

Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO – Get Rating) have been given a consensus recommendation of “Buy” by the nine analysts that are currently covering the company, Marketbeat Ratings reports. Nine investment analysts have rated the stock with a buy rating. The average 1 year price target among brokers that have covered the stock in […]

Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO – Get Rating) rose 6.8% during mid-day trading on Tuesday . The company traded as high as $15.82 and last traded at $15.60. Approximately 573,840 shares changed hands during trading, a decline of 77% from the average daily volume of 2,492,654 shares. The stock had previously closed at $14.60. […]

M28 Capital Management LP lessened its holdings in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO – Get Rating) by 18.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 419,000 shares of the company’s stock after selling 94,300 shares during the period. BridgeBio Pharma […]